Carisoprodol
NDC Package 12634-437-00

11-digit billing NDC: 12634043700

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Carisoprodol is tablets are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults.Carisoprodol tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [ see Dosage and Administration (2)]. Marketed by Apotheca Inc., this product is identified by NDC 12634-437 and is authorized under FDA application ANDA089346.

Identification & Billing

NDC Package Code
12634-437-00
Package Description
10 TABLET in 1 BOTTLE, PLASTIC
Product Code
11-Digit Billing Format
12634043700
RxNorm Crosswalk
RxCUI: 197446 - carisoprodol 350 MG Oral Tablet

Clinical Specifications

Proprietary Name
Carisoprodol
Dosage Form
-
Usage Information
Carisoprodol tablets are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults.Carisoprodol tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [ see Dosage and Administration (2)].

Regulatory & Marketing

Labeler Name
Apotheca Inc.
FDA Application #
ANDA089346
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
10-17-1991
Listing Expiration
12-31-2019
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (12634-437). Click a package code to view its specific billing and regulatory data.

100 TABLET in 1 BOTTLE, PLASTIC
30 TABLET in 1 BLISTER PACK
30 TABLET in 1 BOTTLE
24 TABLET in 1 BOTTLE, PLASTIC
25 TABLET in 1 BOTTLE
20 TABLET in 1 BOTTLE, PLASTIC
15 TABLET in 1 BOTTLE
1 TABLET in 1 BLISTER PACK
5 TABLET in 1 BOTTLE, PLASTIC
6 TABLET in 1 BOTTLE, PLASTIC

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 12634-437-00 identifies a specific commercial package of 10 tablet in 1 bottle, plastic of Carisoprodol, labeled by Apotheca Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Apotheca Inc. on October 17, 1991. The current certification is valid through December 31, 2019.

How is this Apotheca Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 12634043700. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
12634-437-00
11-Digit CMS (5-4-2)
12634-0437-00

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.